# Performance of Elucirem in DSC-MRI Perfusion of Brain Gliomas

> **NCT06057168** · PHASE3 · COMPLETED · sponsor: **Guerbet** · enrollment: 138 (actual)

## Conditions studied

- Brain Tumor, Primary
- Brain Tumor, Recurrent

## Interventions

- **DRUG:** Elucirem
- **DRUG:** Dotarem

## Key facts

- **NCT ID:** NCT06057168
- **Lead sponsor:** Guerbet
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-07
- **Primary completion:** 2024-11-28
- **Final completion:** 2024-11-28
- **Target enrollment:** 138 (ACTUAL)
- **Last updated:** 2026-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06057168

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06057168, "Performance of Elucirem in DSC-MRI Perfusion of Brain Gliomas". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06057168. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*